Literature DB >> 9894896

A statistically defined endpoint titer determination method for immunoassays.

A Frey1, J Di Canzio, D Zurakowski.   

Abstract

Results of immunoassays for which no positive standards are available are often expressed as endpoint titers. The endpoint titer is defined as the reciprocal of the highest analyte dilution that gives a reading above the cutoff. Unfortunately, there is no generally accepted rule for the determination of these cutoff values. In enzyme-linked immunosorbent assays (ELISA) a value two or three times the mean background or negative control reading is sometimes used. Other investigators set the cutoff arbitrarily at a certain absorbance value. These procedures do not provide statistically meaningful information about the risk of overtitration or false low titers. We have solved this problem by devising a practical method for establishing a statistically valid cutoff. The procedure involves calculating the upper prediction limit using the Student t-distribution. The mathematical formula which defines the upper prediction limit is expressed as the standard deviation multiplied by a factor which is based on the number of negative controls and the confidence level (1 - alpha). Appropriate factors are provided for 2 to 30 negative controls and for confidence levels ranging from 95% to 99.9%. Our new method is more reliable than other nonstatistical procedures yet does not require sophisticated computation. It can be applied to a variety of immunoassays provided that negative controls are available.

Mesh:

Year:  1998        PMID: 9894896     DOI: 10.1016/s0022-1759(98)00170-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  220 in total

1.  Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens.

Authors:  S Bas; P Muzzin; B Ninet; J E Bornand; C Scieux; T L Vischer
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Correlations between antibody immune responses at different mucosal effector sites are controlled by antigen type and dosage.

Authors:  D Externest; B Meckelein; M A Schmidt; A Frey
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

4.  Contribution of serum immunoglobulin transudate to the antibody immune status of murine intestinal secretions: influence of different sampling procedures.

Authors:  Barbara Meckelein; Dörthe Externest; M Alexander Schmidt; Andreas Frey
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

5.  Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.

Authors:  Natalie A Hutnick; Devin J F Myles; Bernadette Ferraro; Colleen Lucke; Feng Lin; Jian Yan; Kate E Broderick; Amir S Khan; Niranjian Y Sardesai; David B Weiner
Journal:  Hum Gene Ther       Date:  2012-08-02       Impact factor: 5.695

6.  A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.

Authors:  Karuppiah Muthumani; Darryl Falzarano; Emma L Reuschel; Colleen Tingey; Seleeke Flingai; Daniel O Villarreal; Megan Wise; Ami Patel; Abdullah Izmirly; Abdulelah Aljuaid; Alecia M Seliga; Geoff Soule; Matthew Morrow; Kimberly A Kraynyak; Amir S Khan; Dana P Scott; Friederike Feldmann; Rachel LaCasse; Kimberly Meade-White; Atsushi Okumura; Kenneth E Ugen; Niranjan Y Sardesai; J Joseph Kim; Gary Kobinger; Heinz Feldmann; David B Weiner
Journal:  Sci Transl Med       Date:  2015-08-19       Impact factor: 17.956

7.  Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Authors:  Orly Gershoni-Yahalom; Shimon Landes; Smadar Kleiman-Shoval; David Ben-Nathan; Michal Kam; Bat-El Lachmi; Yevgeny Khinich; Michael Simanov; Itzhak Samina; Anat Eitan; Irun R Cohen; Bracha Rager-Zisman; Angel Porgador
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

8.  Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses.

Authors:  Signe Tandrup Schmidt; Malene Aaby Neustrup; Stine Harloff-Helleberg; Karen Smith Korsholm; Thomas Rades; Peter Andersen; Dennis Christensen; Camilla Foged
Journal:  Pharm Res       Date:  2017-05-17       Impact factor: 4.200

Review 9.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines.

Authors:  Paul E Makidon; Shraddha S Nigavekar; Anna U Bielinska; Nicholas Mank; Abhishek M Shetty; Julie Suman; Jessica Knowlton; Andrzej Myc; Trent Rook; James R Baker
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.